Argus® II Retinal Stimulation System Feasibility Protocol

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Retinitis Pigmentosa
Interventions
DEVICE

Implant of Argus II Retinal Prosthesis

epiretinal implantation of device

Trial Locations (12)

10032

Columbia University, Department of Ophthalmology, Edward S. Harkness Eye Institute, New York

19104

University of Pennsylvania, Scheie Eye Institute, Philadelphia

19107

Wills Eye Hospital, Philadelphia

21205

Johns Hopkins, Wilmer Eye Institute, Baltimore

51116

Puerta de Hierro, Centro Medico, Centro de Retina, Zapopan

75231

Retina Foundation of the Southwest, Dallas

90033

Doheny Eye Institute, Los Angeles

94143

University of California San Francisco, San Francisco

Unknown

Centre d'Investigation Clinique, Service d'Ophtalmologie, Quinze-Vingts National Eye Hospital, 28 rue de Charenton, 75557 Cedex 12, Paris

Clinique d'Ophthalmologie Hopitaux, Universitaires de Geneve 22 rue Alcide Jentzer 1205, Geneva

Manchester Royal Eye Hospital, Manchester

EC1V 2PD

Moorfields Eye Hospital, Vitreoretinal Research Unit, London

All Listed Sponsors
collaborator

National Eye Institute (NEI)

NIH

lead

Second Sight Medical Products

INDUSTRY

NCT00407602 - Argus® II Retinal Stimulation System Feasibility Protocol | Biotech Hunter | Biotech Hunter